"Sezary Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells).
| Descriptor ID |
D012751
|
| MeSH Number(s) |
C04.557.386.480.750.800.775 C15.604.515.569.480.750.800.775 C15.604.515.841 C20.683.515.761.480.750.800.775 C20.683.515.920
|
| Concept/Terms |
Sezary Syndrome- Sezary Syndrome
- Syndrome, Sezary
- Sezary's Lymphoma
- Lymphoma, Sezary's
- Sezary Lymphoma
- Sezarys Lymphoma
- Erythroderma, Sezary
- Sezary Erythroderma
|
Below are MeSH descriptors whose meaning is more general than "Sezary Syndrome".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, T-Cell [C04.557.386.480.750]
- Lymphoma, T-Cell, Cutaneous [C04.557.386.480.750.800]
- Sezary Syndrome [C04.557.386.480.750.800.775]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, T-Cell [C15.604.515.569.480.750]
- Lymphoma, T-Cell, Cutaneous [C15.604.515.569.480.750.800]
- Sezary Syndrome [C15.604.515.569.480.750.800.775]
- Sezary Syndrome [C15.604.515.841]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, T-Cell [C20.683.515.761.480.750]
- Lymphoma, T-Cell, Cutaneous [C20.683.515.761.480.750.800]
- Sezary Syndrome [C20.683.515.761.480.750.800.775]
- Sezary Syndrome [C20.683.515.920]
Below are MeSH descriptors whose meaning is more specific than "Sezary Syndrome".
This graph shows the total number of publications written about "Sezary Syndrome" by people in this website by year, and whether "Sezary Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 2 | 0 | 2 |
| 2008 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sezary Syndrome" by people in Profiles.
-
A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and S?zary syndrome. Br J Dermatol. 2020 02; 182(2):497-498.
-
Genomic profiling of S?zary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet. 2015 Dec; 47(12):1426-34.
-
Genomic analysis of mycosis fungoides and S?zary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015 Sep; 47(9):1056-60.
-
Vitamin D deficiency in mycosis fungoides and S?zary syndrome patients is similar to other cancer patients. Clin Lymphoma Myeloma Leuk. 2014 Dec; 14(6):518-24.
-
Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and S?zary syndrome. Clin Cancer Res. 2015 Jan 15; 21(2):274-85.
-
Identification of p38? as a therapeutic target for the treatment of S?zary syndrome. J Invest Dermatol. 2015 Feb; 135(2):599-608.
-
Disappearance of seborrheic keratoses following treatment with methotrexate. Cutis. 2013 Jul; 92(1):E2-3.
-
A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013 Sep; 49(13):2859-68.
-
Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series. Cancer. 2013 Feb 15; 119(4):825-31.
-
Dendritic cells and cutaneous T-cell lymphomas. G Ital Dermatol Venereol. 2011 Apr; 146(2):103-13.